NasdaqGS:INO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Inovio Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: INO's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

17.7%

INO

4.4%

US Biotechs

1.3%

US Market


1 Year Return

386.9%

INO

27.2%

US Biotechs

21.0%

US Market

Return vs Industry: INO exceeded the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: INO exceeded the US Market which returned 20.9% over the past year.


Shareholder returns

INOIndustryMarket
7 Day17.7%4.4%1.3%
30 Day24.1%14.5%12.1%
90 Day7.1%12.5%4.8%
1 Year386.9%386.9%29.3%27.2%23.7%21.0%
3 Year172.2%172.2%25.6%19.1%46.6%36.8%
5 Year80.5%80.5%16.9%8.8%94.6%73.2%

Long-Term Price Volatility Vs. Market

How volatile is Inovio Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inovio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

6.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate INO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate INO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: INO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: INO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INO is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Inovio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

49.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INO's revenue (42.6% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: INO's revenue (42.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Inovio Pharmaceuticals performed over the past 5 years?

-29.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INO is currently unprofitable.

Growing Profit Margin: INO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INO is unprofitable, and losses have increased over the past 5 years at a rate of 29.4% per year.

Accelerating Growth: Unable to compare INO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: INO has a negative Return on Equity (-55.95%), as it is currently unprofitable.


Next Steps

Financial Health

How is Inovio Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: INO's short term assets ($377.1M) exceed its short term liabilities ($41.3M).

Long Term Liabilities: INO's short term assets ($377.1M) exceed its long term liabilities ($72.6M).


Debt to Equity History and Analysis

Debt Level: INO's debt to equity ratio (16.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if INO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: INO has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 25.3% each year.


Next Steps

Dividend

What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

J. Kim (51 yo)

11.42yrs

Tenure

US$2,588,534

Compensation

Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD2.59M) is below average for companies of similar size in the US market ($USD4.18M).

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
J. Kim
CEO, President & Director11.42yrsUS$2.59m1.25%
$ 25.8m
Peter Kies
Chief Financial Officer18.42yrsUS$1.14m0.073%
$ 1.5m
Jacqueline Shea
Chief Operating Officer1.67yrsUS$1.26m0.0070%
$ 145.7k
Laurent Humeau
Chief Scientific Officer1.67yrsUS$972.53k0.014%
$ 299.3k
Ben Matone
Director of Investor Relations2.92yrsno datano data
Jeffrey Richardson
Vice President of Communications & Strategic Relations1.17yrsno datano data
E. Brandreth
Senior Vice President of Quality Assuranceno datano datano data
Jessica Lee
Senior Vice President of Clinical Operations & Global Integrationno datano datano data
Prakash Bhuyan
Senior Vice President of Clinical Development0.083yrno datano data
Ami Brown
Senior Vice President of Regulatory Affairsno datano datano data
Jeffrey Skolnik
Senior Vice President of Clinical Development0.083yrno datano data
Robert Juba
Senior Vice President of Biological Manufacturing & Clinical Supply Management0.083yrno datano data

1.7yrs

Average Tenure

53.5yo

Average Age

Experienced Management: INO's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
J. Kim
CEO, President & Director11.42yrsUS$2.59m1.25%
$ 25.8m
Wendy Yarno
Independent Director2.92yrsUS$127.56k0.014%
$ 297.7k
Lota Zoth
Independent Director1.83yrsUS$242.43k0.0071%
$ 147.8k
Jay Shepard
Independent Director0.83yrno data0%
$ 0
Simon Benito
Independent Chairman of Board of Directors1.83yrsUS$162.56k0.030%
$ 631.2k
David B. Weiner
Chairman of the Scientific Advisory Board & Director20.83yrsUS$397.59k0.49%
$ 10.1m
Stanley Plotkin
Member of Scientific Advisory Board11.42yrsno datano data
Ann Miller
Independent Director1.67yrsUS$200.44k0.0073%
$ 150.1k
Anthony Ford-Hutchinson
Member of Scientific Advisory Board8.67yrsno datano data
Rafi Ahmed
Member of Scientific Advisory Board2yrsno datano data

2.5yrs

Average Tenure

63.5yo

Average Age

Experienced Board: INO's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.4%.


Top Shareholders

Company Information

Inovio Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inovio Pharmaceuticals, Inc.
  • Ticker: INO
  • Exchange: NasdaqGS
  • Founded: 1979
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.070b
  • Shares outstanding: 169.41m
  • Website: https://www.inovio.com

Number of Employees


Location

  • Inovio Pharmaceuticals, Inc.
  • 660 West Germantown Pike
  • Suite 110
  • Plymouth Meeting
  • Pennsylvania
  • 19462
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 1992
GBMBDB (Deutsche Boerse AG)YesCommon StockDEEURMay 1992
INO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 1992
0A43LSE (London Stock Exchange)YesCommon StockGBUSDMay 1992

Biography

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human p...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/30 23:17
End of Day Share Price2020/11/30 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.